Identification of Prognostic and Predictive Osteosarcoma Biomarkers
Both adolescents and children suffer from osteosarcoma, localized in the metaphysis of the long bones. This is the most common primary high-grade bone tumor in this patient group. Early tumor detection is the key to ensuring effective treatment. Improved osteosarcoma outcomes in clinical trials have...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-02-01
|
Series: | Medical Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3271/7/2/28 |
id |
doaj-4a13cd4f17f2490c9ce1462a46ac4af3 |
---|---|
record_format |
Article |
spelling |
doaj-4a13cd4f17f2490c9ce1462a46ac4af32020-11-24T21:16:12ZengMDPI AGMedical Sciences2076-32712019-02-01722810.3390/medsci7020028medsci7020028Identification of Prognostic and Predictive Osteosarcoma BiomarkersRadoslav Zamborsky0Milan Kokavec1Stefan Harsanyi2Lubos Danisovic3Department of Orthopedics, Faculty of Medicine, Comenius University, Limbova 1, 833 40 Bratislava, SlovakiaDepartment of Orthopedics, Faculty of Medicine, Comenius University, Limbova 1, 833 40 Bratislava, SlovakiaInstitute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Sasinkova 4, 811 08 Bratislava, SlovakiaInstitute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Sasinkova 4, 811 08 Bratislava, SlovakiaBoth adolescents and children suffer from osteosarcoma, localized in the metaphysis of the long bones. This is the most common primary high-grade bone tumor in this patient group. Early tumor detection is the key to ensuring effective treatment. Improved osteosarcoma outcomes in clinical trials have been contingent on biomarker discovery and an evolving understanding of molecules and their complex interactions. In this review, we present a short overview of biomarkers for osteosarcoma, and highlight advances in osteosarcoma-related biomarker research. Many studies show that several biomarkers undergo critical changes with osteosarcoma progression. Growing knowledge about osteosarcoma-related markers is expected to positively impact the development of therapeutics for osteosarcoma, and ultimately of clinical care. It has also become important to develop new biomarkers, which can identify vulnerable patients who should be treated with more intensive and aggressive therapy after diagnosis.https://www.mdpi.com/2076-3271/7/2/28osteosarcomachemotherapytreatmentmalignant bone tumorsbiomarkers |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Radoslav Zamborsky Milan Kokavec Stefan Harsanyi Lubos Danisovic |
spellingShingle |
Radoslav Zamborsky Milan Kokavec Stefan Harsanyi Lubos Danisovic Identification of Prognostic and Predictive Osteosarcoma Biomarkers Medical Sciences osteosarcoma chemotherapy treatment malignant bone tumors biomarkers |
author_facet |
Radoslav Zamborsky Milan Kokavec Stefan Harsanyi Lubos Danisovic |
author_sort |
Radoslav Zamborsky |
title |
Identification of Prognostic and Predictive Osteosarcoma Biomarkers |
title_short |
Identification of Prognostic and Predictive Osteosarcoma Biomarkers |
title_full |
Identification of Prognostic and Predictive Osteosarcoma Biomarkers |
title_fullStr |
Identification of Prognostic and Predictive Osteosarcoma Biomarkers |
title_full_unstemmed |
Identification of Prognostic and Predictive Osteosarcoma Biomarkers |
title_sort |
identification of prognostic and predictive osteosarcoma biomarkers |
publisher |
MDPI AG |
series |
Medical Sciences |
issn |
2076-3271 |
publishDate |
2019-02-01 |
description |
Both adolescents and children suffer from osteosarcoma, localized in the metaphysis of the long bones. This is the most common primary high-grade bone tumor in this patient group. Early tumor detection is the key to ensuring effective treatment. Improved osteosarcoma outcomes in clinical trials have been contingent on biomarker discovery and an evolving understanding of molecules and their complex interactions. In this review, we present a short overview of biomarkers for osteosarcoma, and highlight advances in osteosarcoma-related biomarker research. Many studies show that several biomarkers undergo critical changes with osteosarcoma progression. Growing knowledge about osteosarcoma-related markers is expected to positively impact the development of therapeutics for osteosarcoma, and ultimately of clinical care. It has also become important to develop new biomarkers, which can identify vulnerable patients who should be treated with more intensive and aggressive therapy after diagnosis. |
topic |
osteosarcoma chemotherapy treatment malignant bone tumors biomarkers |
url |
https://www.mdpi.com/2076-3271/7/2/28 |
work_keys_str_mv |
AT radoslavzamborsky identificationofprognosticandpredictiveosteosarcomabiomarkers AT milankokavec identificationofprognosticandpredictiveosteosarcomabiomarkers AT stefanharsanyi identificationofprognosticandpredictiveosteosarcomabiomarkers AT lubosdanisovic identificationofprognosticandpredictiveosteosarcomabiomarkers |
_version_ |
1726016589784940544 |